Get access

Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals

Authors

  • Daniel Q. McNerny,

    Corresponding author
    1. Department of Chemical Engineering, Michigan Nanotechnology Institute for Medicine and Biological Sciences
    • Department of Chemical Engineering, Michigan Nanotechnology Institute for Medicine and Biological Sciences
    Search for more papers by this author
  • Pascale R. Leroueil,

    1. Michigan Nanotechnology Institute for Medicine and Biological Sciences
    Search for more papers by this author
  • James R. Baker

    1. Department of Internal Medicine, Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, MI 48109, USA
    Search for more papers by this author

Abstract

Dendrimer conjugates for pharmaceutical development are capable of enhancing the local delivery of cytotoxic drugs. The ability to conjugate different targeting ligands to the dendrimer allows for the cytotoxic drug to be focused at the intended target cell while minimizing collateral damage in normal cells. Dendrimers offer several advantages over other polymer conjugates by creating a better defined, more monodisperse therapeutic scaffold. Toxicity from the dendrimer, targeted and nonspecific, is not only dependent upon the number of targeting and therapeutic ligands conjugated, but can be influenced by the repeating building blocks that grow the dendrimer, the dendrimer generation, as well as the surface termination. WIREs Nanomed Nanobiotechnol 2010 2 249–259

For further resources related to this article, please visit the WIREs website.

Get access to the full text of this article

Ancillary